ProQR Therapeutics N.V. (PRQR) had a busy Thursday. The small-cap biotech reported positive early-stage clinical data for its investigational RNA editing therapy AX-0810, while simultaneously announcing a $50 million underwritten offering to fund its pipeline. And to top it off, existing shareholder and strategic partner Eli Lilly and Co. (LLY) agreed to buy more shares to keep its stake.

Let's start with the science. ProQR is developing AX-0810, an RNA editing oligonucleotide designed to modulate NTCP, a transporter involved in bile acid uptake into the liver. The goal is to reduce toxic bile acid buildup in cholestatic liver diseases like biliary atresia. The Phase 1 multiple ascending dose study enrolled 33 healthy volunteers, with 24 getting AX-0810 and nine getting a placebo across three dose cohorts. Results from the 3 mg/kg and 6 mg/kg cohorts (22 participants) showed that AX-0810 produced dose-dependent increases in serum bile acids of up to eightfold — well above the company's predefined twofold threshold for meaningful NTCP modulation. Additional biomarker changes, including increased circulating TUDCA levels and higher urinary excretion of conjugated bile acids, further supported target engagement.

Safety-wise, things looked good. No serious adverse events or cases of pruritus were reported. Pharmacokinetic data indicated an estimated half-life of about eight weeks, and hormone levels remained unchanged, suggesting the therapy selectively edits the NTCP bile acid binding pocket without messing with other protein functions. ProQR expects to present the full Phase 1 findings at a medical or scientific conference later this year.

But ProQR isn't stopping there. The company also highlighted progress with AX-0811, a next-generation NTCP-targeting RNA editing candidate developed using its AI-enabled discovery platform. ProQR plans to submit a Clinical Trial Application for AX-0811 in mid-2026.

Now, the financing piece. ProQR priced an underwritten registered direct offering of 27.6 million shares at $1.81 per share, raising gross proceeds of about $50 million. In a separately negotiated transaction, Eli Lilly agreed to purchase approximately 5.1 million shares for about $9.2 million to maintain its pro rata ownership stake. ProQR said the proceeds will fund research and clinical development, working capital, capital expenditures, and other general corporate purposes.

Despite the positive news, ProQR's stock was down 12.71% at $1.58 at the time of publication on Thursday. That's not unusual for a small-cap biotech announcing a dilutive offering — investors often focus on the near-term dilution rather than the long-term potential. But with Eli Lilly's continued backing and promising early data, ProQR has some wind in its sails.